这种药物可能会预防COVID-19患者的呼吸和心血管损伤
![Fig 1. SARS-CoV-2 binds to human epithelial cells and causes permeability. (A) SARS-CoV-2 (1.08 x 105 TCID50/mL) was added to either a control surface (BSA) or human epithelial cells (Caco 2). Cells were allowed to adhere to immobilised SARS-CoV-2 and lysed with pNPP, a fluorescent substrate against alkaline phosphatase expressed within cells. The fluorescent signal emitted by pNPP correlated to the number of cells adhered and was read at 405 nm. Epithelial cells significantly interacted with SARS-CoV-2 (P<0.001; paired t-test, N = 3). (B) Caco-2 was seeded onto transwell inserts and infected with SARS-CoV-2 at MOI = 0.4. Permeability was measured using Fluorescein isothiocyanate-dextran (FITC-Dextran, 40kDa) across 0 hours, 24 hours, and 48 hours. FITC-Dextran passes through the epithelial cells into the lower chamber and is proportionate to their permeability. The extent of permeability was measured by quantifying the fluorescent levels of FITC-Dextran at 490/520 nm. Cell permeability significantly increased throughout the time course (P<0.01; P<0.0001; ANOVA f-value = 46.84, N = 3). 这种药物可能会预防COVID-19患者的呼吸和心血管损伤](https://scx1.b-cdn.net/csz/news/800a/2021/drug-could-potentially.jpg)
科学家们已经发现了一种药物,可以防止导致COVID-19的病毒与人类细胞结合,从而可能防止肺部损伤、血栓形成和败血症的发展。
这项研究由RCSI医学与健康科学大学的研究人员领导,发表在《柳叶刀》上《公共科学图书馆•综合》.
研究人员确定了一种突变,存在于所有的变异病毒到目前为止,在病毒的刺突蛋白中创建了一个额外的结合位点。这一额外的结合位点增加了病毒在体内的影响,包括对肺组织的损害,从而导致COVID-19患者的呼吸问题。
重大的损害肺组织允许病毒从肺部扩散到血液,在那里它可以引起血栓和血管损伤。
在临床前测试中,一种名为西伦吉肽的药物通过阻止病毒粘附在皮肤上,成功地阻止了病毒引起与COVID-19相关的组织损伤细胞类型它们排列在肺和血管上。
该研究的资深作者、RCSI药学和生物分子科学学院副院长Steve Kerrigan教授说:“在这种治疗方法用于患者之前,还需要进行更多的临床前和临床测试,但结果非常有希望。”
“我们必须继续为许多无法获得疫苗的人以及突破性感染患者开发COVID-19治疗方法。我们在实验室的研究表明,西伦吉肽有可能显著减少与COVID-19相关的死亡。”
更多信息:Danielle Nader等人,SARS-CoV-2在COVID-19期间使用主要内皮整合素αvβ3引起体外血管调节异常,《公共科学图书馆•综合》(2021)。DOI: 10.1371 / journal.pone.0253347